超越Kt/V:将透析充分性重新定义为靶向心血管风险降低
本叙述性综述指出心血管疾病是维持性透析患者主要死因,传统每周三次透析以清除小分子为主而非心血管保护。综述评估了高通量在线血液透析滤过、更频繁/夜间/长时透析、中截留膜、个体化透析液钾钠及递增透析等策略的心血管获益证据,认为硬终点证据有限,未来试验应机制特异且终点匹配干预。
要点
- 传统每周三次透析以清除小分子为核心,未以心血管保护为目标。
- 高通量在线血液透析滤过部分研究显示生存改善,但结果跨试验不一致。
- 更频繁/夜间/长时透析改善左室质量等中间终点,硬终点证据有限。
核心结论
- 未来试验应多中心、表型富集、机制特异、样本量充足且终点经裁定。
- 终点应与干预匹配:钾策略用节律监测,钠/容量干预用心脏磁共振和客观容量评估,膜策略用炎症、营养、血管和临床综合结局。
研究设计与样本
- 叙述性综述,评估针对透析相关心血管应激的透析策略。
主要发现
- 高通量在线血液透析滤过随机试验和个体患者数据荟萃分析中,部分研究报道较传统血液透析改善生存。
- 更频繁、夜间和长时透析方案改善左室质量、血压、磷酸盐控制、超滤强度和治疗耐受性等中间终点。
- 中截留膜扩展血液透析改善较大中分子清除,但心血管获益未证实。
- 个体化透析液钾和钠处方是靶向心律失常风险、容量负荷、血压和心脏重构的精准透析方法,但需确证性终点试验。
- 递增透析可能在选择性新入透析患者中保留残余肾功能,但心血管获益易受选择偏倚影响。
临床怎么用
- 临床可考虑更频繁、夜间或长时透析以改善左室质量、血压和磷酸盐控制等中间终点。
- 个体化透析液钾和钠处方可针对心律失常风险和容量负荷,但需等待确证性终点试验。
- 递增透析可用于选择性新入透析患者以保留残余肾功能,但需注意选择偏倚。
局限性
- 高通量在线血液透析滤过结果跨试验不一致,治疗实施、普遍性和机制尚存问题。
- 更频繁、夜间和长时透析的硬终点证据有限。
- 中截留膜扩展血液透析的心血管获益未证实。
- 个体化透析液钾和钠处方缺乏确证性终点试验。
- 递增透析的心血管获益易受选择偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular disease remains the leading cause of death in patients receiving maintenance dialysis, whereas conventional thrice-weekly hemodialysis was developed primarily around small-solute clearance rather than cardiovascular protection. AIM: This narrative review examines dialysis strategies intended to mitigate cardiovascular stress arising from cyclic volume loading, rapid ultrafiltration, electrolyte shifts, myocardial stunning, vascular stiffness, inflammation and anemia, middle-molecule toxicity, loss of residual kidney function, and the long interdialytic interval. EVIDENCE SYNTHESIS: Randomized trials and individual-patient-data meta-analyses have evaluated high-dose online hemodiafiltration, with some studies reporting improved survival compared with conventional hemodialysis. Results have varied across trials, and questions remain regarding treatment delivery, generalizability and the mechanisms underlying the observed effects. More frequent, nocturnal, and long-duration dialysis schedules improve intermediate endpoints, including left ventricular mass, blood pressure, phosphate control, ultrafiltration intensity, and treatment tolerance, but hard-outcome evidence remains limited. Expanded hemodialysis with medium cut-off membranes improves clearance of larger middle molecules, although cardiovascular benefit is unproven. Individualized dialysate potassium and sodium prescriptions are physiologically compelling precision-dialysis approaches targeting arrhythmia risk, volume overload, blood pressure, and cardiac remodeling, but definitive endpoint trials are needed. Incremental dialysis might preserve residual kidney function in selected incident patients, but cardiovascular benefit remains vulnerable to selection bias. CONCLUSIONS: Future trials should be multicenter, phenotype-enriched, mechanism-specific, adequately powered, and endpoint-adjudicated. Endpoints should match the intervention: rhythm monitoring for potassium strategies, cardiac magnetic resonance and objective volume assessment for sodium or volume interventions, and integrated inflammatory, nutritional, vascular, and clinical outcomes for membrane-based approaches.
引用
- Zoccali C, Strippoli G, Locatelli F, et al. Beyond Kt/V: Redefining Dialysis Adequacy as Targeted Cardiovascular Risk Reduction. Nephrol Dial Transplant. 2026. PMID: 42813840. doi:10.1093/ndt/gfag223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。